Startseite UR
![]() | Eine Stufe nach oben |
Huber, D., Seitz, S., Kast, K., Emons, G. und Ortmann, Olaf
(2021)
Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.
Journal of Cancer Research and Clinical Oncology 147, S. 2035-2045.
Ortmann, Olaf, Huber, D., Seitz, S., Kast, K. und Emons, G.
(2020)
Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review.
Archives of Gynecology and Obstetrics 302, S. 715-720.
(2020)
Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review.
Archives of Gynecology and Obstetrics 301, S. 875-884.
Volltext nicht vorhanden.
, Rahner, N., Niederacher, D., Fehm, T., Gehrig, A., Mueller-Reible, C., Arnold, N.
, Maass, N., Borck, G., de Gregorio, N., Scholz, C., Auber, B., Varon-Manteeva, R., Speiser, D., Horvath, J., Lichey, N., Wimberger, P., Stark, S., Faust, U., Weber, Bernhard H. F.
, Emons, G., Zachariae, S., Meindl, A., Schmutzler, R. K., Engel, C.
und German Consortium for Hereditary Breast and Ovarian Cancer, .
(2016)
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.
Journal of Medical Genetics 53 (7), S. 465-471.
Volltext nicht vorhanden.
, Schally, A. V.
, Buchholz, S., Seitz, S., Emons, G. und Ortmann, O.
(2012)
Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).
Archives of Gynecology and Obstetrics 286 (2), S. 437-442.
Volltext nicht vorhanden.
Publikationsserver
Publizieren: oa@ur.de
0941 943 -4239 oder -69394
Dissertationen: dissertationen@ur.de
0941 943 -3904
Forschungsdaten: datahub@ur.de
0941 943 -5707